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Background. The growing burden of diabetes mellitus (DM) is posing a threat to global tuberculosis (TB) control. DM triples the 
risk of developing TB, modifies the presenting features of pulmonary TB, and worsens TB treatment outcomes. We aimed to analyze 
the prevalence of DM among TB patients and to describe the characteristics and clinical presentation of TB-DM patients in Europe.
Methods. We performed a cross-sectional survey on the prevalence of DM among consecutively diagnosed adult TB patients in 
11 European TB referral centers located in France, Germany, Greece, Italy, Russia, Slovakia, Spain, and the United Kingdom over the 
period 2007–2015. We also selected DM-TB cases and TB only controls with a 1:3 ratio to perform a case-control analysis, including 
patients selected from the countries mentioned above plus Norway and Ukraine.
Results. Among 3143 TB enrolled patients, DM prevalence overall was 10.7% and ranged from 4.4% in Greece to 28.5% in the 
United Kingdom. Patients’ median ages ranged from 36 to 49 years, and all centers had >60% males; the proportion of foreign-born 
patients varied widely across sites. In the case-control study, DM was independently associated with older age and, among older 
patients, with being foreign-born. Among patients with pulmonary involvement, cavities on chest imaging were more frequently 
observed among those with DM.
Conclusions. Diabetes mellitus represents a challenge for TB control in Europe, especially in foreign-born and in elderly patients. 
Specific screening strategies should be evaluated.
Keywords.  diabetes mellitus; tuberculosis; foreign-born; Europe.
In 2016, an estimated 290 000 new tuberculosis (TB) cases 
and relapses occurred in World Health Organization (WHO) 
European Region countries, equivalent to 31.6 cases per 100 
000 population and representing about 3.0% of the total global 
burden of TB. During the last decade, the European Region 
achieved the fastest decline in the world compared with other 
WHO regions. Nevertheless, there is a need for an even quicker 
decline in TB incidence to meet the targets of End TB Strategy 
by 2035 [1]. In this context, it is essential to address population 
groups that present conditions that increase the risk of develop-
ing active TB disease [2].
Diabetes mellitus (DM) has recently re-emerged as a signif-
icant risk factor for TB. Five systematic reviews that aimed to 
quantify the increased risk of developing TB among people with 
type 2 diabetes published between 2008 and 2018 found that 
DM increases the likelihood of developing TB by 2- to 3-fold 
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[3–7]. According to the WHO, about 15% of TB cases globally 
can be attributed to DM [8], and DM is now the second most 
important risk factor for TB in the central European region and 
other established market economies [9].
The number of people with DM in Europe in 2017 is esti-
mated to be 58 (95% confidence interval [CI], 46.5–79.5) 
million (age-adjusted comparative prevalence, 6.8%; 95% CI, 
5.4%–9.9%), including 22 million undiagnosed cases. Although 
the European Region has the second-lowest age-adjusted com-
parative DM prevalence rate, after the African Region, there are 
still many European countries with relatively high DM preva-
lence rates [10].
A systematic review published in 2017 has reported an over-
all global median DM prevalence among TB patients of 16% 
[11], ranging from 1.9% in Cotonou-Benin to 45% in the Ebeye-
Marshall Islands [12, 13], a higher burden compared with the 
findings of the previous systematic review conducted in 2010 
[14]. This recently published systematic review [11] retrieved 
only 7 studies conducted in low–TB incidence countries, of 
which only 2 were European [15, 16].
Other published studies on DM prevalence among TB 
patients conducted in Europe during the last 2 decades reported 
prevalence rates ranging from 3.2% in Palma de Mallorca 
(Spain) [17] to 14.6% in Finland [18]. A broader survey and a 
comprehensive analysis on the DM-TB comorbidity in Europe 
are not available in the literature. Thus, we have performed a 
study to assess DM prevalence among patients managed for TB 
in clinical centers across Europe and analyzed the sociodemo-
graphic and clinical characteristics of these patients.
METHODS
Study Participants and Study Design
We designed a retrospective cross-sectional survey and a 
case-control study aimed to assess the prevalence of DM among 
TB patients during the period 2007 to 2015 in Europe and to 
identify sociodemographic and clinical-radiological factors 
associated with DM. Members of the Tuberculosis Network 
European Trials group, a network of clinical centers active in 
the field of TB research in Europe, were invited to join the study 
(TBnet; http://www.tbnet.eu) [19].
Retrospective Survey
We included all patients with TB from the participating TBnet 
centers for a period of 1 to 5 years during 2007–2015 depending 
on the local availability of data. Patients with DM were identi-
fied among patients with TB from clinical records and labora-
tory data already available at the participating TBnet centers. 
Patients included in this analysis had either a known diagnosis 
of DM or sufficient clinical or laboratory information to diag-
nose or exclude DM. DM cases were defined according to the 
following criteria: (1) previous diagnosis of DM type 1 or type 
2 (patients with a physician-based diagnosis of DM before TB 
diagnosis and/or currently receiving treatment for DM) or (2) 
patients diagnosed with DM type 1 or type 2 at the time of TB 
diagnosis: (a) 2 fasting glucose tests >126 mg/dL or (b) 1 oral 
glucose tolerance test >200 mg/dL or (c) in a patient with classic 
symptoms of hyperglycemia or hyperglycemic crisis, a random 
plasma glucose level >200 mg/dL during TB treatment and (d) 
1 HbA1c result >6.5 or fasting glucose level >126 mg/dL during 
TB treatment.
Case-Control Study
For each case of DM-TB, the following 3 consecutive TB patients 
without DM, diagnosed in the same center, were selected as 
controls. DM-TB cases for which 3 controls could not be identi-
fied in the same clinical center were excluded from the analysis.
The following data were collected for patients included 
in this analysis: (1) sociodemographic and epidemiological 
information, including country of origin, age, gender, previ-
ous TB diagnosis, excessive alcohol intake, drug abuse, HIV 
status, comorbidities—including long-term steroids, cyto-
toxic treatment, immunosuppressive medications, chronic 
renal failure/liver disease/lung disease, hematological or 
other malignancies, silicosis, gastrectomy, anti–tumor necro-
sis factor treatment; (2) clinical data: respiratory and general 
symptoms, TB localization (pulmonary/extrapulmonary), 
radiological or computed tomography findings (location of 
lung lesions, presence of cavitary lesions), Mycobacterium 
tuberculosis microbiological examinations (smear micros-
copy and culture results), previous TB, DM diagnosis, plasma 
glucose, and glycated hemoglobin results. Regarding migra-
tion status, patients were classified as autochthonous (those 
born in the same country where TB was diagnosed) or for-
eign-born. Countries of birth were grouped according to 
prevalence of DM in the general population, as reported in 
the 2017 Diabetes Atlas [10].
Data were anonymized and exported in a common format 
from local databases, and a central database was created at the 
coordinating center.
Statistical Analysis
Variables that met the P  <  .2 significance level at univariable 
analysis were retained for the multivariable model, which also 
incorporated standard sociodemographic variables. Two dis-
tinct multivariable models were fitted: we used conditional 
logistic regression to generate crude and adjusted odds ratios 
and 95% confidence intervals (CIs) of the association between 
(1) DM and sociodemographic/clinical characteristics among 
all TB patients and (2) DM and clinical/radiological presenta-
tion of TB among cases with pulmonary involvement. To take 
into account the possible correlation that may arise from obser-
vations belonging to the same center, in the conditional logistic 
regression model, robust standard errors were obtained using 
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the option cluster “vce (cluster clustvar)” with the cluster iden-
tifying the TB diagnosis centers. We tested the hypothesis of 
interaction between variables in the model using the Bayesian 
Information Criterion (BIC). All statistical analyses were con-
ducted using StataCorp 2013 (Stata Statistical Software, Release 
13, StataCorp LP, College Station, TX).
Ethics Board Approval
Authorization for the use of personal data for research pur-
poses was first received from the Ethics Committee of the 
Coordinating Centre (INMI Lazzaro Spallanzani) according 
to the regulations of the Italian Data Protection Authority 
(“General Authorisation to Process Personal Data for 
Scientific Research Purposes,” March 1, 2012, as published in 
Italy’s Official Journal No. 72, dated March 26, 2012). Each 
participating center subsequently collected ethical approval 
according to national/local regulations on personal data 
protection.
RESULTS
Thirteen clinical centers located in 10 different European coun-
tries—France (Briis-sous-Forges), Germany (Borstel), Greece 
(Thessaloniki), Italy (Rome and Genova), Norway (Oslo), 
Russia (Volgograd), Slovakia (Vysne Hagy), Spain (Barcelona, 
Madrid and Pontevedra), the United Kingdom (London), and 
Ukraine (Vinnytsia)—participated in this study. The clinical 
centers located in Ukraine and Norway provided data only for 
the case-control study, not for the prevalence study. One center 
reported using random plasma glucose level testing and HbA1c 
determination for screening TB patients for DM, whereas the 
others reported using random or fasting plasma glucose level. 
For DM diagnostic confirmation, all centers reported using 
HbA1c determination.
Study Participant Characteristics
Overall, 3143 TB patients were included in the prevalence 
analysis (Table 1). The percentage of male patients was >60% 
in all centers, and patients’ median ages ranged from 36 to 
49  years. Wide differences were observed in the proportion 
of foreign-born participants among centers (no foreign-born 
individuals in the study populations from Russia and Slovakia; 
intermediate percentages from Madrid, Spain (30.8%), and 
Greece (39.7%), and higher rates in Genova, Italy (69.6%), 
Barcelona, Spain (72.7%), Rome, Italy (74.6%), France (78.4%), 
and the United Kingdom. HIV prevalence was available from 8 
centers and ranged from 0% (Greece) to 15.2% (Russia).
Of the patients included in the analysis, 337 were diagnosed 
with DM, and the overall prevalence was 10.7% (95% CI, 9.7%–
11.9%); in different countries, DM prevalence ranged from 
4.4% in Greece to 28.5% in the United Kingdom. No significant 
difference was found between the 2 centers in Italy, whereas 
the prevalence varied significantly among the 3 Spanish cen-
ters (P < .05 by chi-square test). No significant trends over time 
in DM prevalence in participating centers were observed (data 
not shown). DM prevalence increased with age, more markedly 
among foreign born (Figure 1).
Among 325 TB-DM cases for whom information was avail-
able, 21.8% were newly diagnosed DM cases. DM was more fre-
quently diagnosed at the time of TB diagnosis in foreign-born 
than autochthonous patients (43/148, 29.0%, vs 28/177, 
15.8%; P = .004). Information on DM treatment was available 
for 271/325 (83.4%) DM cases, and 91.9% were in treatment. 
Table 1. Prevalence of Diabetes Mellitus Among Patients With Tuberculosis Diagnosed in 13 European Clinical Centers and Contribution of Centers to a 
Case-Control Study
Center Yearsb
Prevalence Study Case-Control Study
TB, 
No.
Male 
Gender, %
Age, 
Median, y
Foreign- 
Born, % HIV+, %
DM, 
No.
TB-DM/TB%, 
95% CI
DM General Population 
Prevalencea Cases, No.
Controls, 
No.
France 2010–2012 116 83.6 45 78.4 nr 9 7.8, 3.6–14.2 5.2 9 27
Germany 2012–2015 163 65.0 44 66.9 nr 15 9.2, 5.2–14.7 7.9 15 45
Greece 2010–2014 68 73.5 43 39.7 0.0 3 4.4, 0.9–12.3 4.8 3 9
Italy–Genova 2009–2011 79 74.7 38 69.6 8.9 8 10.1, 4.5–19.0 4.9 8 24
Italy–Rome 2007–2012 956 65.3 36 74.6 14.7 63 6.6, 5.1–8.4 4.9 63 189
Norway  2009–2013 Data not available 12 36
Russia 2009–2013 374 78.1 40 0.0 15.2 45 12.0, 8.9–15.8 5.0 45 135
Slovakia 2015 101 79.2 49 0.0 nr 10 9.9, 4.9–17.5 7.2 10 30
Spain–Barcelona 2009–2013 198 81.8 37 72.7 11.6 24 12.1, 7.9–17.5 7.9 24 72
Spain–Pontevedra 2009–2013 394 61.7 46 5.6 4.1 26 6.6, 4.4–9.5 7.9 12 36
Spain–Madrid 2009–2013 266 65.0 42 30.8 12.0 12 4.5, 2.4–7.8 7.9 26 78
Ukraine 2009–2013 Data not available 27 81
United Kingdom 2012–2015 428 64.7 36 85.3 2.1 122 28.5, 24.3–33.0 3.9 71 213
Abbreviations: CI, confidence interval; DM, diabetes mellitus; TB, tuberculosis.
aInternational Diabetes Atlas – 2014.
bDiagnosis periods in case-control studies differ slightly with respect to prevalence period for France and Greece, 2011–2012 and 2010–2013, respectively.
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One-half of patients were treated with oral hypoglycemic drugs 
and the others with insulin.
Associations Between Diabetes in Tuberculosis and Clinical and 
Demographic Characteristics
To analyze the association between DM and demographic and 
clinical characteristics, we compared 325 TB-DM cases and 975 
TB-only controls diagnosed consecutively after each TB-DM 
case in the same center (total 1300) (Table 1). Pulmonary and 
extrapulmonary TB disease were equally distributed among 
cases and controls (pulmonary localization: 229/325, 70.5%, vs 
687/975, 70.5%; extrapulmonary localization: 72/325, 22.2%, vs 
201/975, 20.6%; both pulmonary and extrapulmonary localiza-
tions: 24/325, 7.4%, vs 87/975, 8.9%).
In univariable analysis (Table 2), DM cases were significantly 
older (odds ratio [OR] for age ≥50 years, 3.6; 95% CI, 2.1–6.2; 
P < .001) and more likely to have comorbidities (OR, 1.6; 95% 
CI, 1.0–2.6; P = .058), whereas they were less likely to originate 
from foreign countries (OR, 0.7; 95% CI, 0.5–1.1; P  =  .153). 
There was no evidence of an association between DM and HIV 
infection, country of birth prevalence, previous TB disease, 
excessive alcohol intake, and drug abuse.
The multivariable conditional regression model with an 
interaction term between age and migration status had a bet-
ter fit than the model without it. Other interactions were not 
significant. The final multivariable model, in addition to age, 
migration status, and their interaction, included comorbidities 
also and was adjusted for country of birth by DM prevalence 
and gender. Multivariable analysis confirmed the association 
between DM and older age both among authoctonous and 
among foreign-born (OR, 2.3; 95% CI, 1.1–4.8; P = .026; OR, 
7.3; 95% CI, 5.1–10.5; P < .001, respectively). Among older 
patients DM was associated with being foreign-born rather 
than authoctonous (OR, 2.8; 95% CI, 1.7–4.7; P < .001).  An 
association with comorbidities was not confirmed (Table 2).
To analyze the association between DM and radiological 
and clinical characteristics of pulmonary TB, we compared 
254 cases and 762 controls. At univariable analysis, a positive 
sputum culture was significantly associated with DM (OR, 1.4; 
95% CI, 1.1–1.7; P = .003); moreover, DM diagnosis was more 
likely among patients with radiological evidence of cavities 
(OR, 1.6; 95% CI, 1.0–2.5; P =  .054), with a positive sputum 
smear microscopy (OR, 1.4; 95% CI, 1.0–2.2; P  =  .077), and 
among those reporting the presence of persisting cough (OR, 
1.4; 95% CI, 0.9–2.0; P =  .086). In the multivariable analysis, 
the presence of persisting cough and radiological evidence of 
cavities were more frequent among patients with DM, altough 
no association that was significant at the P  <  .05 level was 
observed. (Table 3).
DISCUSSION
This multicenter study collected DM prevalence data from a 
large population of TB patients attending 11 specialized clinical 
centers in Europe and found a general overall prevalence higher 
than the reported comparative DM prevalence in the general 
European population [10]. This result should nevertheless be 
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Figure 1. Prevalence of diabetes mellitus (DM) among patients with tuberculosis (TB) by age and migration status.
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considered cautiously, as the studied population was not a ran-
dom sample of patients diagnosed with TB in countries where 
the study was carried out.
A wide variation of DM prevalence was reported across 
countries (4.4% in Greece to 28.5% in the United Kingdom) 
and across some centers (4.5% to 12.1% in 3 centers in Spain) 
with different annual caseloads; nevertheless, most centers, 
as expected, reported a DM prevalence higher than the com-
parative DM prevalence for the general population of each 
respective country and higher than previous findings from 
single-center or nationwide population-based studies on 
TB-DM patients performed in Europe [15, 20–28]. One study 
conducted in Madrid [20] reported a DM prevalence almost 
double (8.6%) that collected by our study site in Madrid 
(4.5%). The population analyzed by Fortún et al. [20] was nev-
ertheless larger and recruited during a more extended period. 
The highest DM prevalence rate was reported in the United 
Kingdom, where it was 4 times greater than comparative 
DM prevalence for the UK general population. This could be 
explained by the specific characteristics of this study popula-
tion, including the extremely high proportion of foreign-born 
patients. Differences in diagnostic practices for DM may also 
contribute to differences in DM prevalence in different cen-
ters. Taken together, however, these studies suggest that DM 
Table 2. Case-Control Study on Tuberculosis in Diabetes Mellitus in Patients Enrolled in 13 European Centers
 
TB-DM
(n = 325), No. (%)
TB
(n = 975), No. (%)
Univariablea  Multivariablea
OR (95% CI) P Interaction Term OR (95% CI) P
Age class, y
 <50 157 (48.3) 744 (76.3) 1  Authoctonous 1  
    Foreign-born 0.9 (0.5–1.7) .687
 ≥50 168 (51.7) 231 (23.7) 3.6 (2.1–6.2) <.001 Authoctonous 1  
    Foreign-born 2.8 (1.7–4.7) <.001
Migration status        
 Authoctonous 176 (54.1) 486 (49.9) 1  Age < 50 y 1  
     Age ≥ 50 y 2.3 (1.1–4.8) .026
 Foreign-born 149 (45.9)  489 (50.1) 0.7 (0.5–1.1) .153 Age < 50 y 1  
     Age ≥ 50 y 7.3 (5.1–10.5) <.001
Country of birth by DM prevalenceb      
 ≤6.5% 107 (32.9) 321 (32.9) 1   1  
 6.6%–8.3% 119 (36.6) 313 (32.1) 1.3 (0.8–2.0) .313  1.3 (0.7–2.3) .424
 ≥8.4% 99 (30.5) 341 (35.0) 0.8 (0.5–1.3) .357  0.8 (0.5–1.2) .231
Gender        
 Female 90 (27.7) 290 (29.7) 1   1  
 Male 235 (72.3) 685 (70.3) 1.1 (0.8–1.6) .607  1.0 (0.6–1.6) .920
Previous TB disease  
 No 247 (76.0) 767 (78.7) 1     
 Yes 53 (16.3) 130 (13.3) 1.3 (0.8–2.1) .353    
 Not available 25 (7.7) 78 (8.0) 1.0 (0.7–1.5) .987    
Heavy drinking  
 No 222 (68.3) 636 (65.2) 1     
 Yes 38 (11.7) 122 (12.5) 0.9 (0.6–1.3) .536    
 Not available 65 (20.0) 217 (22.3) 0.7 (0.4–1.3) .259    
Injecting drug users  
 No 232 (71.4) 725 (74.4) 1     
 Yes 14 (4.3) 44 (4.5) 1.0 (0.3–3.7) .976    
 Not available 79 (24.3) 206 (21.1) 2.2 (0.9–5.3) .093    
HIV status  
 Negative 255 (78.5) 779 (79.9) 1     
 Positive 23 (7.1) 84 (8.6) 0.8 (0.2–3.1) .776    
 Not available 47 (14.5) 112 (11.5) 1.4 (1.0–1.8) .025    
Other comorbidities  
 No 231 (71.1) 697 (71.5) 1   1  
 Yes 70 (21.5) 137 (14.0) 1.6 (1.0–2.6) .058  1.1 (0.7–1.6) .711
 Not available 24 (7.4) 141 (14.5) 0.4 (0.1–1.8) .235  0.3 (0.1–1.5) .144
Abbreviations: CI, confidence interval; DM, diabetes mellitus; OR, odds ratio; TB, tuberculosis.
aConditional logistic regression model with robust standard error estimated by including the center as the cluster variable.
bInternational Diabetes Atlas – 2014.
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patients constitute a relevant proportion of individuals with TB 
in European countries.
Older age was identified as a risk factor for TB-DM comorbid-
ity, in agreement with a recent systematic review [11] and with 
other European studies [15, 23, 25]. This association may reflect 
the current distribution of DM among the general population 
in Europe. Moreover, older-aged (≥50 years) foreign-born DM 
prevalence was approximately 3 times higher than that among 
authoctonous individuals in that age group.
An extensive systematic review has identified both male [29] 
and female [11] gender as risk factors for TB-DM comorbidity. 
We could not find any association with gender.
The proportion of foreign-born TB patients varied widely 
across TB reference centers, and this could reflect differences 
in patterns of migration and population structure among the 
participating countries (ie, the United Kingdom, France; Italy 
vs Russia or Slovakia) or when differences were found in the 
same country (in the case of Spain) or among different cit-
ies in the same country. Foreign-born TB patients were more 
likely to have DM compared with authoctonous individuals if 
aged ≥50 years, independent of DM prevalence in their coun-
try of origin, consistent with previous studies from high-in-
come countries [25, 30, 31]. People migrating from low- and 
middle-income countries may have a higher prevalence of DM 
compared with the native population, and also somehow higher 
than in persons from the same population who remain in their 
country of origin [32]. Nevertheless, opposite results (ie, lower 
risk of DM in foreign-born TB patients compared with authoc-
tonous individuals or lower risk of TB in foreign-born DM 
patients compared with authoctonous) have been reported by 
previous studies conducted in Italy [24], Spain [15, 17], Portugal 
[23], and Japan [33].
As in other studies, DM was mainly diagnosed before a 
TB diagnosis in our patient population. However, approx-
imately one-fifth of the patients with DM, most of whom 
were foreign-born, were identified at the time of TB diagno-
sis, possibly reflecting difficulties in accessing or obtaining 
specialized medical care. Poor glycemic control has been 
shown to increase the risk of TB for patients with DM [34], 
so we could hypothesize that the high proportion of undiag-
nosed DM, especially among foreign-born patients, may be 
itself a further factor contributing to the risk of developing 
TB in this population. The existence of a sizeable propor-
tion of TB patients in whom DM was not diagnosed until 
TB diagnosis, who were possibly at risk of uncontrolled DM, 
emphasizes the relevance of DM screening, especially in 
Table 3. Case-Control Study on Tuberculosis in Diabetes Mellitus in Patients Enrolled in 13 European Centers—Analysis of Radiological and Clinical 
Characteristics Among Patients With Pulmonary Involvment
   Univariablea Multivariablea b
 TB-DM (n = 254), No. (%) TB (n = 762), No. (%) OR (95% CI) P OR (95% CI) P
TB site of disease
 Pulmonary 228 (89.8) 681 (89.4) 1    
 Pulmonary and extrapulmonary 26 (10.2) 81 (10.6) 0.9 (0.6–1.5) .857   
CXR cavities       
 No 94 (37.0) 341 (44.7) 1  1  
 Yes 146 (57.5) 365 (47.9) 1.6 (1.0–2.5) .054 1.6 (0.9–2.8) .110
 Not available 14 (5.5) 56 (7.4) 0.8 (0.3–1.9) .584 1.0 (0.5–2.1) .992
Sputum smear microscopy–positive      
 No 77 (30.3) 283 (37.1) 1  1  
 Yes 156 (61.4) 416 (54.6) 1.4 (1.0–2.2) .077 1.3 (0.7–2.7) .425
 Not available 21 (8.3) 63 (8.3) 1.2 (0.6–2.4) .558 1.2 (0.5–2.9) .667
Sputum culture–positive      
 No 26 (10.4) 100 (13.1) 1  1  
 Yes 201 (79.1) 577 (75.7) 1.4 (1.1–1.7) .003 0.9 (0.5–1.8) .888
 Not available 27 (10.6) 85 (11.1) 1.1 (0.8–1.6) .416 1.1 (0.6–2.0) .676
Weight loss       
 No 109 (42.9) 315 (41.3) 1    
 Yes 127 (50.0) 342 (48.9) 1.1 (0.6–1.8) .794   
 Not available 18 (7.1) 105 (13.8) 0.4 (0.1–1.3) .117   
Persisting cough       
 No 42 (16.5) 146 (19.2) 1  1  
 Yes 199 (78.3) 523 (68.6) 1.4 (0.9–2.0) .086 1.5 (0.9–2.3) .092
 Not available 13 (5.1) 93 (12.2) 0.4 (0.1–2.0) .261 0.5 (0.1–1.7) .248
Abbreviations: CI, confidence interval; CXR, chest x-ray; DM, diabetes mellitus; OR, odds ratio; TB, tuberculosis.
aConditional logistic regression model with robust standard error estimated by including the center as the cluster variable.
bAdjusted for age, gender, and HIV status.
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patients migrating from high–TB burden countries. A policy 
of bidirectional low-cost screening (screening DM patients 
for TB and TB patients for DM) would be an effective way 
of identifying a vulnerable population for both diseases 
promptly.
The relatively higher level of incidence and prevalence of dia-
betes among people living with HIV, and particularly among 
those who are receiving antiretroviral treatment, warrants 
the screening of people living with HIV for hyperglycemia, 
both at time of enrollment and during the follow-up period 
of HIV treatment [35]. Nevertheless, the complex interaction 
among DM, HIV, and TB is still unclear: A case-control study 
from Tanzania identified DM as a risk factor for TB in the 
non-HIV-infected, but not in HIV-infected patients [36]. In 
our study, no association with HIV infection was identified. 
A negative association between being HIV-positive and DM 
prevalence among TB patients was reported by other stud-
ies also conducted in Europe—Italy [25], Spain [15, 17], and 
Portugal [23]. It has been suggested that the very strong asso-
ciation between HIV and TB may obscure the role of DM [6, 
37]; however, a recent study concluded that DM may further 
increase the risk of developing TB among persons living with 
HIV [38].
DM has been found to be an independent risk factor for 
higher prevalence or greater severity of some symptoms such 
as cough, hemoptysis, fever, and delayed sputum conversion 
[39–41]. Data indicating higher bacillary burden in sputa are 
conflicting [42–44]. In our study, no significant differences in 
the prevalence of symptoms were recorded among the totality 
of TB patients with pulmonary involvement, with or without 
DM. Previous studies show that cavities on chest x-rays are 
significantly more frequent among TB-DM patients [15, 25, 
45], suggesting that DM patients with TB are on average more 
infectious than those without DM [46]. In our study, pulmo-
nary cavities were more frequent among DM patients than 
those without DM, although this difference was not statistically 
significant.
Limitations
Due to its voluntary nature and retrospective and multi-
centric design, our study has some methodological limita-
tions. Representativeness and reliability of DM prevalence 
data are limited due to the participation of few countries and 
to the relatively small sample. Missing data on HIV status and 
the heterogeneity of recruited populations among centers with 
foreign-born patient proportions may have caused over- or 
underestimation of some associations. Partial duplication of 
data has to be acknowledged for 1 of the Italian study centers 
(Rome) [45]. Despite planning at the protocol stage, the infor-
mation obtained on glucose test results and glycemic control was 
incomplete. TB outcomes, income status, and urban residency 
were not investigated.
CONCLUSIONS
To our knowledge, this is the first multicenter study reporting 
on DM in TB patients in Europe, where DM represents a chal-
lenge for TB control. Older patients and foreign-born individ-
uals emerged as vulnerable populations, and this suggests that 
they should be a priority target for TB screening among those 
with DM.
Further studies to analyze the association of DM with drug 
resistance and with TB outcomes, to evaluate whether TB-DM 
patients contribute to enhanced TB transmission in low–TB 
burden countries, and to obtain broader cross-sectional and 
prospective data that may help in assessing the feasibility and 
cost-effectiveness of TB-DM bi-directional screening are 
needed.
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